BEAM-302
Small molecule
Beam TherapeuticsBEAM-302 is one of 17 small molecule programs targeting Alpha-1 Antitrypsin Deficiency. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Alpha-1 Antitrypsin Deficiency
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPhase 2
Benadryl
PParkedale
Phase 1
SAR447537
SanofiPhase 2
Zofran
NovartisPreclinical
RG6026
RochePhase 1
Alvelestat
UUniversity of Alabama at Birmingham
Phase 2
Biological NTLA-2002
Intellia TherapeuticsPhase 2
Tylenol
KKenvue Brands
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BEAM-302. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company